Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3463
Structure:
Synonyms:
1A Brand of Gemfibrozil
2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid
2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure
2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure
2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
25812-30-0
5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid
5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid
5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid
AB00052003
AC-4225
AC1L1FZT
AC1Q2JC7
AIDS-121781
AIDS121781
AKOS001606691
Alphapharm Brand of Gemfibrozil
Apo Gemfibrozil
Apo-Gemfibrozil
ApoGemfibrozil
Apotex Brand of Gemfibrozil
ARONIS24091
Ausgem
Bayvit Brand of Gemfibrozil
Bayvit, Gemfibrozilo
BB_SC-4837
Bexal Brand of Gemfibrozil
Bexal, Gemfibrozilo
Biochemie Brand of Gemfibrozil
Bolutol
BPBio1_000251
BRD-K11129031-001-05-1
BRN 1881200
Brozil
BSPBio_000227
BSPBio_002060
Bull Brand of Gemfibrozil
C07020
C15H22O3
Cantabria Brand of Gemfibrozil
CAS-25812-30-0
CCG-40111
CCRIS 318
CHEBI:5296
Chem mart Brand of Gemfibrozil
Chem mart Gemfibrozil
CHEMBL457
Cholespid
CI 719
CI-719
CI719
Clearol
CPD000058393
D00334
D015248
DB01241
DBL Gemfibrozil
Decrelip
DivK1c_000138
Douglas Brand of Gemfibrozil
EINECS 247-280-2
Elmogan
Farmasierra Brand of Gemfibrozil
Faulding Brand of Gemfibrozil
Ferrer Brand of Gemfibrozil
Fetinor
Fibratol
Fibrocit
G9518_SIGMA
GEM
Gem-S
Gemcor, Lopid, Jezil, Gen-Fibro, Gemfibrozil
Gemd
Gemfi 1A Pharma
Gemfibril
Gemfibromax
Gemfibrosil
GEMFIBROZIL
Gemfibrozil (JAN/USP/INN)
GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL))
Gemfibrozil [USAN:BAN:INN]
Gemfibrozil, GenRX
Gemfibrozil, Healthsense
Gemfibrozil, SBPA
Gemfibrozil-Supplied by Selleck Chemicals
Gemfibrozilo
Gemfibrozilo Bayvit
Gemfibrozilo Bexal
Gemfibrozilo Ur
Gemfibrozilo [INN-Spanish]
Gemfibrozilum
Gemfibrozilum [INN-Latin]
Gemhexal
Gemlipid
Gemnpid
Gen Gemfibrozil
Gen-Fibro
Gen-Gemfibrozil
GenGemfibrozil
Genlip
Genpharm Brand of Gemfibrozil
GenRX Gemfibrozil
Gevilon
Gevilon Uno
GFZ
Gozid
Healthsense Brand of Gemfibrozil
Healthsense Gemfibrozil
Hexal Brand of Gemfibrozil
Hidil
Hipolixan
HMS1568L09
HMS1920B07
HMS2090K14
HMS2091H11
HMS2095L09
HMS2230H24
HMS3259M12
HMS500G20
I01-1855
IDI1_000138
Innogem
Innogen
Ipolipid
Ipsen Brand of Gemfibrozil
Jezil
KBio1_000138
KBio2_001305
KBio2_003873
KBio2_006441
KBio3_001280
KBioGR_000964
KBioSS_001305
Lanaterom
Lifibron
Lipazil
Lipigem
Lipira
Lipizyl
Lipox Gemfi
Lipozid
Lipur
Litarek
Lopid
Lopid (TN)
Lopid R
Low-Lip
LS-1085
Menarini Brand of Gemfibrozil
Micolip
MLS000028421
MLS001055364
NCGC00016794-01
NCGC00016794-02
NCGC00016794-03
NCGC00016794-04
NCGC00016794-05
NCGC00016794-06
NCGC00016794-07
NCGC00016794-08
NCGC00016794-09
NCGC00016794-10
NCGC00016794-11
NCGC00022722-03
NCGC00022722-04
NCGC00022722-05
NCGC00022722-06
NCGC00022722-07
nchembio790-comp22
NINDS_000138
Normolip
Novo Gemfibrozil
Novo-Gemfibrozil
Novopharm Brand of Gemfibrozil
Nu Gemfibrozil
Nu Pharm Brand of Gemfibrozil
Nu-Gemfibrozil
Nu-Pharm Brand of Gemfibrozil
NuGemfibrozil
Parke Davis Brand of Gemfibrozil
Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-
PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL)
Pfizer Brand of Gemfibrozil
Pharmascience Brand of Gemfibrozil
Pilder
PMS Gemfibrozil
PMS-Gemfibrozil
Polyxit
Prestwick0_000214
Prestwick1_000214
Prestwick2_000214
Prestwick3_000214
Prestwick_637
Progemzal
Quimifar Brand of Gemfibrozil
Reducel
Regulip
Renabrazin
S1729_Selleck
SAM002564211
SBB012457
SBPA Gemfibrozil
Sigma Brand of Gemfibrozil
Sinelip
SMR000058393
SPBio_001174
SPBio_002148
SPECTRUM1500313
Spectrum2_001097
Spectrum3_000440
Spectrum4_000562
Spectrum5_000750
Spectrum5_001991
Spectrum_000825
SR-01000000056
SR-01000000056-6
ST072198
STK618740
Synbrozil
Taborcil
TAD Brand of Gemfibrozil
Tentroc
Terry White Chemists Brand of Gemfibrozil
Terry White Chemists Gemfibrozil
TEVA-A
TL8002081
Trialmin
UNII-Q8X02027X3
United Drug Brand of Gemfibrozil
Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-
Warner Lambert Brand of Gemfibrozil
Warner-Lambert Brand of Gemfibrozil
WL-Gemfibrozil
ATC-Codes:
Side-Effects:
Side-EffectFrequency
dyspepsia0.020499999
abdominal pain0.014857144
diarrhea0.0128333345
fatigue0.0071666664
nausea0.0050
vomiting0.0049999994
acute appendicitis0.004666667
atrial fibrillation0.0040
eczema0.0039999993
vertigo0.0033333332
constipation0.0031666665
rash0.0031428565
headache0.0024285712
flatulence0.0010
blurred vision0.0
myalgia0.0
urticaria0.0
thrombocytopenia0.0
myopathy0.0
pancreatitis0.0
impotence0.0
jaundice0.0
leukopenia0.0
synovitis0.0
rhabdomyolysis0.0
pruritus0.0
peripheral neuritis0.0
eosinophilia0.0
edema0.0
alopecia0.0
anemia0.0
angioedema0.0
arthralgia0.0
photosensitivity0.0
cholecystitis0.0
cholelithiasis0.0
dizziness0.0
somnolence0.0
dermatitis0.0
decreased libido0.0
exfoliative dermatitis0.0
vasculitis0
bacterial infections0
convulsions0
cataract0
liver function tests abnormal0
anaphylaxis0
epigastric pain0
hepatoma0
urinary tract infection0
cerebral hemorrhage0
lupus0
gout0
confusion0
common cold0
pain0
colitis0
paresthesia0
cough0
syncope0
chest pain0
peripheral vascular disorder0

Target

show target details
Uniprot ID:CP1A2_HUMAN
Synonyms:
CYPIA2
Cytochrome P450 1A2
P(3)450
P450 4
P450-P3
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2HI4
Structure:
2HI4

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----

References:

11602509
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.. X Wen; J S Wang; J T Backman; K T Kivist÷; P J Neuvonen (2001) Drug metabolism and disposition: the biological fate of chemicals display abstract
The in vitro inhibitory effects of gemfibrozil on cytochrome P450 (CYP) 1A2 (phenacetin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2C9 (tolbutamide hydroxylation), CYP2C19 (S-mephenytoin 4'-hydroxylation), CYP2D6 (dextromethorphan O-deethylation), CYP2E1 (chlorzoxazone 6-hydroxylation), and CYP3A4 (midazolam 1'-hydroxylation) activities were examined using pooled human liver microsomes. The in vivo drug interactions of gemfibrozil were predicted in vitro using the [I]/([I] + K(i)) values. Gemfibrozil strongly and competitively inhibited CYP2C9 activity, with a K(i) (IC(50)) value of 5.8 (9.6) microM. In addition, gemfibrozil exhibited somewhat smaller inhibitory effects on CYP2C19 and CYP1A2 activities, with K(i) (IC(50)) values of 24 (47) microM and 82 (136) microM, respectively. With concentrations up to 250 microM, gemfibrozil showed no appreciable effect on CYP2A6, CYP2D6, CYP2E1, and CYP3A4 activities. Based on [I]/([I] + K(i)) values calculated using peak total (or unbound) plasma concentration of gemfibrozil, 96% (56%), 86% (24%), and 64% (8%) inhibition of the clearance of CYP2C9, CYP2C19, and CYP1A2 substrates could be expected, respectively. In conclusion, gemfibrozil inhibits the activity of CYP2C9 at clinically relevant concentrations, and this is the likely mechanism by which gemfibrozil interacts with CYP2C9 substrate drugs, such as warfarin and glyburide. Gemfibrozil may also impair clearance of CYP2C19 and CYP1A2 substrates, but inhibition of other CYP isoforms is unlikely.
11602509
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.. X Wen; J S Wang; J T Backman; K T Kivist÷; P J Neuvonen (2001) Drug metabolism and disposition: the biological fate of chemicals display abstract
The in vitro inhibitory effects of gemfibrozil on cytochrome P450 (CYP) 1A2 (phenacetin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2C9 (tolbutamide hydroxylation), CYP2C19 (S-mephenytoin 4'-hydroxylation), CYP2D6 (dextromethorphan O-deethylation), CYP2E1 (chlorzoxazone 6-hydroxylation), and CYP3A4 (midazolam 1'-hydroxylation) activities were examined using pooled human liver microsomes. The in vivo drug interactions of gemfibrozil were predicted in vitro using the [I]/([I] + K(i)) values. Gemfibrozil strongly and competitively inhibited CYP2C9 activity, with a K(i) (IC(50)) value of 5.8 (9.6) microM. In addition, gemfibrozil exhibited somewhat smaller inhibitory effects on CYP2C19 and CYP1A2 activities, with K(i) (IC(50)) values of 24 (47) microM and 82 (136) microM, respectively. With concentrations up to 250 microM, gemfibrozil showed no appreciable effect on CYP2A6, CYP2D6, CYP2E1, and CYP3A4 activities. Based on [I]/([I] + K(i)) values calculated using peak total (or unbound) plasma concentration of gemfibrozil, 96% (56%), 86% (24%), and 64% (8%) inhibition of the clearance of CYP2C9, CYP2C19, and CYP1A2 substrates could be expected, respectively. In conclusion, gemfibrozil inhibits the activity of CYP2C9 at clinically relevant concentrations, and this is the likely mechanism by which gemfibrozil interacts with CYP2C9 substrate drugs, such as warfarin and glyburide. Gemfibrozil may also impair clearance of CYP2C19 and CYP1A2 substrates, but inhibition of other CYP isoforms is unlikely.
12065698
Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.. Jun-Sheng Wang; Xia Wen; Janne T Backman; Pertti J Neuvonen (2002) The Journal of pharmacology and experimental therapeutics display abstract
The effect of human serum albumin (Hsa) and human liver cytosol (Hlc) on the in vitro enzyme kinetics of the formation of hydroxytolbutamide (CYP2C9 marker reaction) and the inhibitory effect of gemfibrozil on tolbutamide hydroxylation were examined using human liver microsomes. The addition of Hsa greatly decreased the unbound concentrations of tolbutamide and gemfibrozil in the incubation medium, whereas Hlc only slightly decreased them. The unbound K(m) value for tolbutamide hydroxylation was 123 microM without Hsa and Hlc, and 73, 88, and 64 microM in the presence of Hsa (5 mg/ml), Hlc (0.5 mg/ml), and Hsa plus Hlc, respectively. The predicted in vivo hepatic clearance (CL(h)) of tolbutamide based on enzyme kinetics without Hsa and Hlc (0.06 ml/min/kg) was 40% of its in vivo clearance (0.15 ml/min/kg) based on published data. Addition of 5 mg/ml Hsa and 0.5 mg/ml Hlc to the incubation medium distinctly improved the prediction, with the coaddition of Hsa and Hlc yielding the most accurate value (0.14 ml/min/kg). The K(i) (6 microM) of gemfibrozil for CYP2C9, calculated using total drug concentrations, was increased by Hlc (8 microM), Hsa (40 microM), or both (72 microM). However, when the unbound substrate and inhibitor concentrations were considered, the K(i) (6 microM without Hsa and Hlc) was not markedly altered by Hsa (4 microM), Hlc (8 microM), or both Hsa and Hlc (9 microM). The present findings suggest that the addition of Hsa and Hlc to microsomal incubation media may yield enzyme kinetic estimates more comparable with in vivo results.